126 related articles for article (PubMed ID: 26519191)
1. Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir.
Mogalian E; German P; Kearney BP; Yang CY; Brainard D; McNally J; Moorehead L; Mathias A
Clin Pharmacokinet; 2016 May; 55(5):605-13. PubMed ID: 26519191
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Mogalian E; German P; Kearney BP; Yang CY; Brainard D; Link J; McNally J; Han L; Ling J; Mathias A
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193657
[TBL] [Abstract][Full Text] [Related]
3. Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers.
Mogalian E; Stamm LM; Osinusi A; Brainard DM; Shen G; Ling KHJ; Mathias A
Clin Infect Dis; 2018 Aug; 67(6):934-940. PubMed ID: 29522076
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.
Brieva T; Rivero A; Rivero-Juarez A
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):483-490. PubMed ID: 28165830
[TBL] [Abstract][Full Text] [Related]
6. Concomitant Intake of Coca-Cola to Manage the Drug-Drug Interaction Between Velpatasvir and Omeprazole Studied in Healthy Volunteers.
van Seyen M; Colbers A; Abbink EJ; Drenth JPH; Burger DM
Clin Pharmacol Ther; 2019 Nov; 106(5):1093-1098. PubMed ID: 31313296
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
Everson GT; Towner WJ; Davis MN; Wyles DL; Nahass RG; Thuluvath PJ; Etzkorn K; Hinestrosa F; Tong M; Rabinovitz M; McNally J; Brainard DM; Han L; Doehle B; McHutchison JG; Morgan T; Chung RT; Tran TT
Ann Intern Med; 2015 Dec; 163(11):818-26. PubMed ID: 26551051
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
10. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.
Kanda T
Hepatol Int; 2017 Jan; 11(1):38-44. PubMed ID: 27282879
[TBL] [Abstract][Full Text] [Related]
11. Sofosbuvir/Velpatasvir (Epclusa) for Hepatitis C.
Sokol R
Am Fam Physician; 2017 May; 95(10):664-666. PubMed ID: 28671408
[No Abstract] [Full Text] [Related]
12. Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.
Kahveci AS; Tahan V
Turk J Gastroenterol; 2016 Mar; 27(2):205-6. PubMed ID: 27015627
[No Abstract] [Full Text] [Related]
13. Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
Brennan BJ; Poirier A; Moreira S; Morcos PN; Goelzer P; Portmann R; Asthappan J; Funk C; Smith PF
Clin Pharmacokinet; 2015 May; 54(5):537-49. PubMed ID: 25488594
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection.
Bourgeois S; Van Vlierberghe H; Moreno C; Orlent H; Nevens F; Arastéh K; Horsmans Y; Schattenberg JM; Buggisch P; Francque S; Vijgen L; Kakuda TN; Hoeben E; Luo D; Vandebosch A; Jacquemyn B; Van Remoortere P; Verloes R
BMC Gastroenterol; 2017 Feb; 17(1):26. PubMed ID: 28187751
[TBL] [Abstract][Full Text] [Related]
15. New Drug Treats All Genotypes of Chronic HCV.
Aschenbrenner DS
Am J Nurs; 2016 Oct; 116(10):27. PubMed ID: 27684768
[No Abstract] [Full Text] [Related]
16. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions with new hepatitis C oral drugs.
Soriano V; Labarga P; Barreiro P; Fernandez-Montero JV; de Mendoza C; Esposito I; Benítez-Gutiérrez L; Peña JM
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):333-41. PubMed ID: 25553890
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
19. A simple and sensitive HPLC-FL method for bioanalysis of velpatasvir, a novel hepatitis C virus NS5A inhibitor, in rat plasma: Investigation of factors determining its oral bioavailability.
Choi E; Han DG; Park JE; Lee HY; Yoo JW; Jung Y; Song IS; Yoon IS
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1208():123399. PubMed ID: 35921698
[TBL] [Abstract][Full Text] [Related]
20. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.
Eley T; Garimella T; Li W; Bertz RJ
Clin Pharmacokinet; 2015 Dec; 54(12):1205-22. PubMed ID: 26177803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
